Evolution in the Understanding of the Etiology of Staghorn Renal Lithiasis

Main Article Content

José Armando Pérez Espinoza
Alexandra Corona Arroyo
Angelina Pérez Espinoza

Abstract

Staghorn lithiasis, characterized by renal calculi that extensively occupy the renal collecting system, poses significant medical challenges due to high morbidity and mortality rates. Traditionally attributed primarily to recurrent urinary tract infections caused by urease-producing bacteria, recent studies indicate a shift toward an increased prevalence of metabolic stones. This change may be linked to rising obesity and metabolic syndrome rates. Historical perspectives emphasized struvite stones, associated with infections, but emerging data reveal a notable proportion of calcium phosphate and mixed stones, suggesting a complex interplay between metabolic factors and infection. Analysis of stone composition in patients has shown that metabolic abnormalities are common, emphasizing the need for comprehensive evaluations beyond infectious risk. Understanding this evolving etiology is crucial for guiding treatment and improving patient outcomes.

Article Details

How to Cite
José Armando Pérez Espinoza, Alexandra Corona Arroyo, & Angelina Pérez Espinoza. (2024). Evolution in the Understanding of the Etiology of Staghorn Renal Lithiasis. International Journal of Medical Science and Clinical Research Studies, 4(10), 1909–1910. https://doi.org/10.47191/ijmscrs/v4-i10-33
Section
Articles

References

I. Miller N., Borofsky M. (2020). Evaluation and Medical Management of Urinary Lithiasis. Alan W. Partin (Ed.). Campbel-Walsh-Wein Urology, twelfth edition. (pp. 2036-2068). Canada. Elsevier.

II. Diri A., Diri B. (2018). Management of staghorn renal stones. Renal Failure. 40 (1). 357-362.

III. Terry R., Preminger G. (2020). Metabolic evaluation and medical management of staghorn calculi. Asian Journal of Urology. 7. 122-129.

IV. Sharbaugh A., Morgan T., et al. (2019). Contemporary best practice in the management of staghorn calculi. Therapeutic Advances in Urology. 11. 1-9.